¡PrEP Ya! Latin America wants PrEP, and Brazil leads the way
The Lancet - "Brazil has long been at the forefront of HIV treatment and prevention in Latin America. It was the first country in the region to make highly active antiretroviral therapy freely available and participated in the iPrEx study, which reported the efficacy of pre-exposure prophylaxis (PrEP) with daily oral emtricitabine and tenofovir disoproxil fumarate to prevent HIV acquisition in men who have sex with men (MSM) and transgender women.
In The Lancet HIV, Beatriz Grinsztejn and colleagues3 report another first in Latin America: a demonstration trial of PrEP among MSM and transgender women vulnerable to HIV under real-world conditions in the Brazilian public health system. The results, namely that PrEP was effective, drug adherence was good, and sexual risk compensation was not observed, will surprise few in the HIV prevention field." (Photo: Prefeitura de Olinda/flilckr, CC BY 2.0)